Chongqing Lummy Pharmaceutical Co Ltd operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Chongqing Lummy Pharmaceutical Co Ltd with three other
companies in this sector in CHINA :
Shandong Shanda Wit Science and Technology Co Ltd
sales of 1.80 billion Chinese Renmimbi [US$252.19 million]
of which 60%
Jinhe Biotechnology Co Ltd
(1.78 billion Chinese Renmimbi [US$249.59 million]
of which 91%
was Domestic), and
Shanghai Shenqi Pharmaceutical Investment Management CoLtd
(1.93 billion Chinese Renmimbi [US$270.08 million]
of which 75%
was Pharmaceutical Manufacturing).
During the year ended December of 2019, sales at
Chongqing Lummy Pharmaceutical Co Ltd were 1.86 billion Chinese Renmimbi (US$260.47 million).
increase of 19.0%
versus 2018, when the company's sales were 1.56 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Chongqing Lummy Pharmaceutical Co Ltd
(and since 2014, sales have increased a total of 104%).
Sales of Chemical Distribution saw an increase
that was more than double the company's growth rate: sales were up
8,876.0% in 2019, from
1.08 million Chinese Renmimbi to 97.16 million Chinese Renmimbi.
Chongqing Lummy Pharmaceutical Co Ltd also saw significant increases in sales in
Drug Sales Service (up 302.3% to 41.75 million Chinese Renmimbi)
Other Operations (up 438.4% to 19.83 million Chinese Renmimbi)